At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
E2814drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating E2814 for Alzheimer Disease. Completed, enrolled 8 participants across 3 sites in 2 countries.
Detailed Summary
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJul 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedJul 21, 2021
Enrollment StartJun 28, 2021
Primary CompletionMay 24, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.9 years ago
Interventions
E2814drug
E2814 intravenous infusion.